Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model–Based Prediction An economic model was developed to estimate the ...
Fam-Trastuzumab Deruxtecan in HER2/Neu-Expressing Serous Endometrial Cancer The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...
MI Cancer Seek™ is the first FDA-approved test combining whole exome and transcriptome sequencing for solid tumor molecular profiling. The test identifies patients for targeted therapies in breast, ...
“NeXT Dx incorporates a range of features and comprehensive genome variant detection methods that lead to improved disease management and possible enhanced clinical utility.” “The NeXT Dx clinical ...
Genomic testing based on chromosome microarray (CMA) and Next Generation Sequencing (NGS) revolutionized clinical genetics. That said, microarray, targeted panel, exome and generic whole genome ...
Caris to provide DNA and RNA molecular testing to support patient identification and enrollment for Merus’ Zenocutuzumab Phase 1/2 eNRGy trial UTRECHT, The Netherlands and CAMBRIDGE, Mass. and IRVING, ...
Every cell makes its own proteins by accessing the genetic information on its genes. Changes in this information, called mutations, may ruin the function of the affected proteins. In oncology, this is ...
DURHAM, N.C.--(BUSINESS WIRE)--BioSkryb Genomics, a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback